Form 4 for GNLX GENELUX Corp
Accepted 2023-12-18 00:00:00 ET · period of report 2023-12-15 · accession 0001209191-23-058954 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-12-18 | 2023-12-15 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale | $13.16 | -32.5K | 5,803 | -85% | -$428.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-15 | S | D | 5,803 | $14.18 | 0 | D | — | — | (F2) The weighted average sale price for the transaction reported was $14.1763, and the range of prices were between $13.80 and $14.535. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2023-12-15 | S | D | 26,732 | $12.94 | 5,803 | D | — | — | (F1) The weighted average sale price for the transaction reported was $12.9401, and the range of prices were between $12.69 and $13.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |